Difference between revisions of "Etoposide (Vepesid)"
Jump to navigation
Jump to search
m |
m |
||
| Line 27: | Line 27: | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
*[[Gallbladder cancer]] | *[[Gallbladder cancer]] | ||
| + | *[[Gestational trophoblastic neoplasia]] | ||
*[[Hemophagocytic lymphohistiocytosis]] | *[[Hemophagocytic lymphohistiocytosis]] | ||
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
| Line 157: | Line 158: | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
[[Category:Gallbladder cancer medications]] | [[Category:Gallbladder cancer medications]] | ||
| + | [[Category:Gestational trophoblastic neoplasia medications]] | ||
[[Category:Hemophagocytic lymphohistiocytosis medications]] | [[Category:Hemophagocytic lymphohistiocytosis medications]] | ||
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
Revision as of 14:23, 1 May 2022
General information
Class/mechanism: Topoisomerase II inhibitor. Causes DNA strand breaks by interacting with DNA-topoisomerase II or by forming free radicals. Causes arrest at the G2 portion of the cell cycle, with dose dependent effects: at high concentrations, cells entering mitosis undergo lysis; at low concentrations, cells are inhibited from entering prophase.[1][2]
Route: IV, PO
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- Carcinoma of unknown primary
- Adrenocortical carcinoma
- Adult T-cell leukemia-lymphoma
- Anaplastic glioma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Burkitt lymphoma
- Cholangiocarcinoma
- CNS lymphoma
- Diffuse large B-cell lymphoma
- Esophageal cancer
- Ewing sarcoma
- Extranodal NK- and T-cell lymphoma, nasal type
- Follicular lymphoma
- Gallbladder cancer
- Gestational trophoblastic neoplasia
- Hemophagocytic lymphohistiocytosis
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Kaposi sarcoma
- Langerhans cell histiocytosis
- Low-grade glioma
- Mantle cell lymphoma
- Mediastinal gray-zone lymphoma
- Medulloblastoma
- Multiple myeloma
- NK- and T-cell lymphoma
- Non-small cell lung cancer
- Osteosarcoma
- Ovarian cancer
- Peripheral T-cell lymphoma
- Primary mediastinal B-cell lymphoma
- Rhabdomyosarcoma
- Soft tissue sarcoma
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Transformed lymphoma
Patient drug information
- Etoposide (Vepesid) package insert[1]
- Etoposide (Vepesid) patient drug information (Chemocare)[3]
- Etoposide (Vepesid) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 11/10/1983: Initial FDA approval for refractory testicular tumors
- Unclear date: Approed for small cell lung cancer, in combination with cisplatin, as first-line treatment
Also known as
- Code names: VP-16, VP-TEC, VP 16213
- Generic name: etoposide phosphate
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Aside | Beposid | Bioposide | Celltop | Citodox | Epocin | Eposid | Eposide |
| Eposido | Eposin | Epsidox | ETO | Etocris | Etomedac | Etonolver | Etopofos |
| Etopophos | Etopos | Etoposid | Etoposido | Etopoxan | Etopul | Etosid | Etosin |
| Eunades CS | Euvaxon | Exitop | Fytop | Fytosid | Labimion | Lastet | Lastet S |
| Neoplaxol | Nexvep | Onkoposid | Optasid | Percas | Posid | Posidon | Posyd |
| Riboposid | Sintopozid | Toposar | Toposide | Toposin | Topresid | Tosuben | Vepefos |
| Vepesid | Vepeside | Vepsid | Vepside | ||||
References
Categories:
- Drugs
- Intravenous medications
- Oral medications
- Irritant
- Topoisomerase inhibitors
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- Carcinoma of unknown primary medications
- Adrenocortical carcinoma medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic glioma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Burkitt lymphoma medications
- Cholangiocarcinoma medications
- CNS lymphoma medications
- Diffuse large B-cell lymphoma medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Ewing sarcoma medications
- Extranodal NK- and T-cell lymphoma, nasal type medications
- Follicular lymphoma medications
- Gallbladder cancer medications
- Gestational trophoblastic neoplasia medications
- Hemophagocytic lymphohistiocytosis medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Langerhans cell histiocytosis medications
- Low-grade glioma medications
- Mantle cell lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Medulloblastoma medications
- Multiple myeloma medications
- NK- and T-cell lymphoma medications
- Non-small cell lung cancer medications
- Osteosarcoma medications
- Ovarian cancer medications
- Peripheral T-cell lymphoma medications
- Primary mediastinal B-cell lymphoma medications
- Rhabdomyosarcoma medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Transformed lymphoma medications
- Kaposi sarcoma medications
- FDA approved in 1983
- WHO Essential Cancer Medicine